Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 19% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancercellchemotherapyradiationgreater
  Phrases that lowered it: efficacy andand safetytopicalclinicalrelapsed
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 10.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Number of arms: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 150 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 95.9% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 20.0% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Allocation: non randomized (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma NCT01334502 · started 2012 · scored riskier than 53% of active trials completed
• A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00622258 · started 2008 · scored riskier than 10% of active trials completed
• Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma NCT01665768 · started 2012 · scored riskier than 98% of active trials completed
• Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma NCT01854606 · started 2013 · scored riskier than 33% of active trials completed
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy NCT00790036 · started 2009 · scored riskier than 51% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.